We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
St. Jude Medical (STJ) Launches Trial for Amulet Occluder
Read MoreHide Full Article
St. Jude Medical, Inc. , a global medical device company, announced that it has initiated a trial for its AMPLATZER Amulet occlude. The trial willevaluate the safety and effectiveness of its AMPLATZER Amulet Left Atrial Appendage Occluder. The occluderwill be used to close the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AF). The first implant of the study took place at North Mississippi Medical Center in Tupelo, MSby Dr. Jim Stone.
The AMPLATZER Amulet occluder works by blocking the LAA at its opening. This minimizes chances of blood clots in the LAA and theirmigrationinto the bloodstream. The AMPLATZER Amulet occlude is the second-generation St. Jude Medical LAA occlusion device. It is built with a longer lobe and waist than the previous version and designed to allow easier and more stable placement, which could result in shorter procedure times for patients. The AMPLATZER Amulet device is also offered in eight sizes to accommodate varying anatomies.
The AMPLATZER Amulet IDE trial is randomizedand will enroll patients inup to 100 sites in the U.S. and an additional 50 sites internationally. The enrolled patients will be randomly assigned to receive either the St. Jude Medical Amulet device or an FDA approved LAA closure device in the control arm of the study. Data collected across all trial sites will be used to support the FDA approval of the AMPLATZER Amulet Occluder.
Headquartered in St. Paul, MN, St. Jude Medical hasapproximately 18,000 employeesworldwide and focuses on five major areas that include heart failure, atrial fibrillation, neuromodulation, traditional cardiac rhythm management and cardiovascular.
Zacks Rank & Key Picks
Currently, St. Jude has a Zacks Rank #3 (Hold). Better-ranked medical stocks are IDEXX Laboratories Inc. (IDXX - Free Report) , Masimo Corp. (MASI - Free Report) and Quidel Corp. (QDEL - Free Report) . All these stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
St. Jude Medical (STJ) Launches Trial for Amulet Occluder
St. Jude Medical, Inc. , a global medical device company, announced that it has initiated a trial for its AMPLATZER Amulet occlude. The trial willevaluate the safety and effectiveness of its AMPLATZER Amulet Left Atrial Appendage Occluder. The occluderwill be used to close the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AF). The first implant of the study took place at North Mississippi Medical Center in Tupelo, MSby Dr. Jim Stone.
The AMPLATZER Amulet occluder works by blocking the LAA at its opening. This minimizes chances of blood clots in the LAA and theirmigrationinto the bloodstream. The AMPLATZER Amulet occlude is the second-generation St. Jude Medical LAA occlusion device. It is built with a longer lobe and waist than the previous version and designed to allow easier and more stable placement, which could result in shorter procedure times for patients. The AMPLATZER Amulet device is also offered in eight sizes to accommodate varying anatomies.
The AMPLATZER Amulet IDE trial is randomizedand will enroll patients inup to 100 sites in the U.S. and an additional 50 sites internationally. The enrolled patients will be randomly assigned to receive either the St. Jude Medical Amulet device or an FDA approved LAA closure device in the control arm of the study. Data collected across all trial sites will be used to support the FDA approval of the AMPLATZER Amulet Occluder.
ST JUDE MEDICAL Price
ST JUDE MEDICAL Price | ST JUDE MEDICAL Quote
Headquartered in St. Paul, MN, St. Jude Medical hasapproximately 18,000 employeesworldwide and focuses on five major areas that include heart failure, atrial fibrillation, neuromodulation, traditional cardiac rhythm management and cardiovascular.
Zacks Rank & Key Picks
Currently, St. Jude has a Zacks Rank #3 (Hold). Better-ranked medical stocks are IDEXX Laboratories Inc. (IDXX - Free Report) , Masimo Corp. (MASI - Free Report) and Quidel Corp. (QDEL - Free Report) . All these stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>